CN109069509B - 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗 - Google Patents

索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗 Download PDF

Info

Publication number
CN109069509B
CN109069509B CN201780014430.0A CN201780014430A CN109069509B CN 109069509 B CN109069509 B CN 109069509B CN 201780014430 A CN201780014430 A CN 201780014430A CN 109069509 B CN109069509 B CN 109069509B
Authority
CN
China
Prior art keywords
sorafenib
phosphoramidate prodrug
troxacitabine
trosacitabine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780014430.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109069509A (zh
Inventor
马克·阿尔贝特拉
安德斯·埃内罗特
比约恩·克拉松
弗雷德里克·厄贝里
约翰·奥德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir AB filed Critical Medivir AB
Priority to CN202010727607.5A priority Critical patent/CN111956646B/zh
Publication of CN109069509A publication Critical patent/CN109069509A/zh
Application granted granted Critical
Publication of CN109069509B publication Critical patent/CN109069509B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201780014430.0A 2016-03-02 2017-02-28 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗 Active CN109069509B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010727607.5A CN111956646B (zh) 2016-03-02 2017-02-28 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1650274-2 2016-03-02
SE1650274 2016-03-02
SE1651204 2016-09-08
SE1651204-8 2016-09-08
PCT/SE2017/050186 WO2017151044A1 (en) 2016-03-02 2017-02-28 Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010727607.5A Division CN111956646B (zh) 2016-03-02 2017-02-28 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗

Publications (2)

Publication Number Publication Date
CN109069509A CN109069509A (zh) 2018-12-21
CN109069509B true CN109069509B (zh) 2020-10-16

Family

ID=59744330

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010727607.5A Active CN111956646B (zh) 2016-03-02 2017-02-28 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗
CN201780014430.0A Active CN109069509B (zh) 2016-03-02 2017-02-28 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010727607.5A Active CN111956646B (zh) 2016-03-02 2017-02-28 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗

Country Status (17)

Country Link
US (2) US10456413B2 (enExample)
EP (1) EP3423061B1 (enExample)
JP (1) JP6968080B2 (enExample)
KR (1) KR102703122B1 (enExample)
CN (2) CN111956646B (enExample)
AU (2) AU2017227516B2 (enExample)
CA (1) CA3014769C (enExample)
ES (1) ES2987989T3 (enExample)
HR (1) HRP20241508T1 (enExample)
HU (1) HUE068940T2 (enExample)
MY (1) MY198140A (enExample)
PL (1) PL3423061T3 (enExample)
RS (1) RS66090B1 (enExample)
RU (1) RU2018134336A (enExample)
SG (1) SG11201806855WA (enExample)
WO (1) WO2017151044A1 (enExample)
ZA (1) ZA201805445B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3423061T3 (pl) 2016-03-02 2024-12-16 Medivir Aktiebolag Leczenie skojarzone sorafenibem lub regorafenibem i amidofosforanowym prolekiem troksacytabiny
JP2021512875A (ja) * 2018-02-02 2021-05-20 カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． 細胞免疫療法の組み合わせ
JP7337539B2 (ja) 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
US20240024342A1 (en) * 2020-04-15 2024-01-25 Medivir Ab Miv-818/lenvatinib combination therapy for liver cancer
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물
IT202000022636A1 (it) 2020-09-25 2022-03-25 Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma”
WO2024205477A1 (en) * 2023-03-30 2024-10-03 Medivir Ab Method for treating liver cancers using fostroxacitabine bralpamide, an immune checkpoint inhibitor and a vegf antagonist

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030922A2 (en) * 2000-10-13 2002-04-18 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
WO2005009961A2 (en) * 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2015081133A2 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
WO2015081297A1 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE602004011340T2 (de) 2003-05-20 2008-11-06 Bayer Healthcare Llc Diaryl-harnstoffe mit kinasehemmender wirkung
CN102671196B (zh) * 2006-04-05 2014-12-03 诺华股份有限公司 用于治疗癌症的治疗剂的组合
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
CN102190616B (zh) 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
EP4140487A1 (en) 2012-04-13 2023-03-01 Epizyme Inc Combination therapy for treating cancer
CN103570613B (zh) 2012-07-18 2016-06-15 苏州泽璟生物制药有限公司 氘代ω-二苯基脲或其盐的多晶型物
WO2014022116A2 (en) 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
WO2014047199A1 (en) * 2012-09-19 2014-03-27 The Research Foundation For The State University Of New York Novel prodrugs for selective anticancer therapy
SG10201911558UA (en) * 2014-08-25 2020-01-30 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
PL3423061T3 (pl) * 2016-03-02 2024-12-16 Medivir Aktiebolag Leczenie skojarzone sorafenibem lub regorafenibem i amidofosforanowym prolekiem troksacytabiny

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030922A2 (en) * 2000-10-13 2002-04-18 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
WO2005009961A2 (en) * 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2015081133A2 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
WO2015081297A1 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection

Also Published As

Publication number Publication date
WO2017151044A1 (en) 2017-09-08
AU2017227516A1 (en) 2018-08-30
JP6968080B2 (ja) 2021-11-17
KR102703122B1 (ko) 2024-09-04
CN111956646B (zh) 2023-07-25
US10456413B2 (en) 2019-10-29
CN111956646A (zh) 2020-11-20
JP2019507764A (ja) 2019-03-22
ES2987989T3 (es) 2024-11-18
PL3423061T3 (pl) 2024-12-16
BR112018067387A2 (pt) 2019-01-02
EP3423061A1 (en) 2019-01-09
EP3423061C0 (en) 2024-08-07
AU2022203761B2 (en) 2024-06-13
US20200009166A1 (en) 2020-01-09
RU2018134336A (ru) 2020-04-02
HUE068940T2 (hu) 2025-02-28
AU2017227516B2 (en) 2022-03-03
US20190091246A1 (en) 2019-03-28
CA3014769C (en) 2024-01-09
EP3423061A4 (en) 2019-11-13
KR20180118745A (ko) 2018-10-31
EP3423061B1 (en) 2024-08-07
AU2022203761A1 (en) 2022-06-16
RS66090B1 (sr) 2024-11-29
ZA201805445B (en) 2019-07-31
RU2018134336A3 (enExample) 2020-05-22
CN109069509A (zh) 2018-12-21
MY198140A (en) 2023-08-07
SG11201806855WA (en) 2018-09-27
HRP20241508T1 (hr) 2025-01-03
US10960017B2 (en) 2021-03-30
CA3014769A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
CN109069509B (zh) 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗
CN101678029B (zh) 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途
WO2017037292A1 (en) Combination of a dhodh inhibitor and a her inhibitor for use in the treatment of cancer
TW201216963A (en) Novel compounds and compositions for the inhibition of NAMPT
CN106255756A (zh) 肝癌的索拉非尼‑微rna联合疗法
AU2021255043B9 (en) MIV-818/lenvatinib combination therapy for liver cancer
JP2022532189A (ja) 軟部肉腫の併用療法用キノリン誘導体
HK40040637B (zh) 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗
HK40040637A (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
HK40000353B (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
HK40000353A (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
HK40081068A (en) Miv-818/lenvatinib combination therapy for liver cancer
BR112018067387B1 (pt) Uso de um agente terapêutico
JPWO2017030146A1 (ja) 胆道癌治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40000353

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant